After ping-ponging, proposed data exclusivity periods now more in line with current framework
Politics, Policy & Law
Data Byte
BMS awaits decisions on two new indications for Breyanzi; therapies from Ascendis, Dynavax also up for approvals
Management Tracks
Plus: Dubensky to lead ImmuneSensor and updates from NORD and Epsilogen
BioCentury ISSN 1097-7201